TASIGNA is now indicated for patients newly diagnosed with Ph+
Is it possible to improve on imatinib?
TASIGNA has significantly more power to reduce progression vs imatinib to AP/BC than imatinib in patients with newly diagnosed Ph+ CML.
What outcomes can I expect in imatinib-resistant or -intolerant patients?
Achieve high overall survival with TASIGNA in heavily pretreated imatinib-resistant or -intolerant patients.
Can tolerability help patients maintain therapy?
TASIGNA has a favorable tolerability profile in newly diagnosed patients.